Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age

Human Vaccines

Volumn 3, Issue 1, 2007, Pages 14-22

  Marchetti, Monia ^a   Kühnel, Ursula M ^b   Colombo, Giorgio L ^c   Esposito, Susanna ^d   Principi, Nicola ^d  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Berna Biotech AG   (Switzerland)

^c SAVE Studi Analisi Valutazioni Economiche   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

6 to 60 month old children; Cost effectiveness; Virosomal adjuvanted influenza vaccine

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; CEPHALOSPORIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHILD HOSPITALIZATION; COHORT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; FEVER; HEALTH CARE COST; HEALTH SERVICE; HOUSEHOLD; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; ITALY; NORMAL HUMAN; PRESCHOOL CHILD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

EID: 33847010239     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.1.3657     Document Type: Article

References (64)

1. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, Blanchi C, Colombo GL, Prinicipi N. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 2006; 24:629-35.
2. Esposito S, Gasparini R, Bosis S, Marchisio P, Tagliabue C, Tosi S, Bianchi C, Crovari P, Principi N. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005; 11:933-6.
3. Prinicipi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22:52007-10.
4. Heikkinen T, Booy R, Campins M, Finn A, Olcen P, Peltola H, Rodrigo C, Schmitt HJ, Schumacher F, Teo S, Weil-Olivier C. Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatrics 2006; 165:223-8.
5. Navarro-Mari JM, Perez-Ruiz M, Cantudo-Munoz P, Petit-Gancedo C, Jimenez-Valera M, Rosa-Fraile M. Influenza Surveillance Network in Andalusia, Spain: Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol 2005; 58:275-9.
6. Italian Ministry of Health. Recommendations for control and prevention of influenza (season 2005/2006). http://www.ministerosalute.it/imgs/ C_17_normativa_566_allegato. pdf (accessed in February 2006).
7. Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: Systematic review. Lancet 2005; 365:773-80.
8. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: A meta-analysis. Vaccine 2005; 23:2851-61.
9. Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kosinetz C, Hessel C, Glezen WP. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in communiry-based, nonrandomized, open-label trial. Pediatrics 2005; 116:e397-407.
10. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005; 116:153-9.
11. Istituto Superiore della Sanità. Progetto INFLUNET. http://www.flu.iss.it/download.htm (accessed in February 2006).
12. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-42.
13. Canadian Paediatric Society (CPS). Recommendations for the use of influenza vaccine for children. http://www.cps.ca/english/statements/ID/ID04-01. htm (accessed in February 2006).
14. World Health Organization. Weekly epidemiological record. 2005; 80:277-88.
15. Ontario Ministry of Health and Long-Term Care. Public information. Immunization: Influenza vaccine. http://www.health.gov.on.ca/english/public/ program/pubhealth/flu/flu_05/factsheets/flu_vaccine.html (accessed in February 2006).
16. National demographic statistics and forecasts. http://demo.istat.it/ pop2004/index.html (accessed in October 2005).
17. National statistics: Family composition in the year 2001. http://dawinci.istat.it/daWinci/jsp/MD/dawinciMD.jsp (accessed in February 2006).
18. Italian National Influenza Network. INFLUNET. http://www.influnet.unige. it (accessed in February 2006).
19. Istituto Superiore di Sanità. INFLUNET. http://www.flu.iss.it (accessed February 2006).
20. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment for influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
21. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, Wright PF. Burden of interpandemic influenza in children younger than 5 years: A 25-year prospective study. J Infect Dis 2002; 185:147-52.
22. Montes M, Vicente D, Perez-Yarza EG, Cilla G, Perez-Trallero E. Influenza-related hospitalisations among children aged less than 5 years old in the Basque Country, Spain: A 3-year study (July 2001-June 2004). Vaccine 2005; 23:4302-6
23. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K. Influenza and the rates of hospitalisation for respiratory disease among infants and young children. N Engl J Med 2003; 342:232-9.
24. O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, Yu XJ, Platt R, Lieu TA. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004; 113:585-93.
25. Neuzil KM, Meilen BG, Wright PF, Mitchel Jr EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225-31.
26. Weycker D, Edelsberg J, Halloran ME, Longini Jr IM, Nizam A, Ciuryla V, Oster G. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005; 23:1284-93.
27. Salleras L, Dominiquez A, Pumarola T, Prat A, Marcos RA, Artigas R, Bau A, Brotons J, Bruna X, Catala P, Carreras E, Cuadra D, Gatell A, Millet S, Oller J, Raga E. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: A prospective cohort study. Vaccine 2006; 24:6638-42.
28. Fujieda M, Maeda A, Kondo K, Kaji M, Hirota Y. Inactivated influenza vaccine effectiveness in children under 6 years of age during the 2002-2003 season. Vaccine 2006; 25:957-63.
29. Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kosinezt A, Riggs MW, Fewlass C, Halloran ME, Longini Jr IM, Glezen WP. Direct and total effectiveness of in the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004; 158:65-73.
30. Jordan R, Connock M, Albon E, Fry-Smith A, Olowokure B, Hawker J, Burls A. Universal vaccination of children against influenza: Are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006; 24:1047-62.
31. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005; 23:1540-8.
32. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, Waecker N, Cox NJ. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284:1677-82.
33. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H+N+) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991; 163:300-4.
34. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: Effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156:986-91.
35. Esposito S, Marchisio P, Cavagna R, Gironi S, Bosis S, Lambertini L, Droghetti R, Principi N. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 2003; 21:3162-8.
36. Center For Disease Control and Prevention (CDC). Estimated influenza vaccination coverage among adults and children - United States, September 1, 2004-January 31, 2005. MMWR 2005; 54:304-7.
37. Grant VJ, Le Saux N, Plint AC, Correll R, Gaboury I, Ellis E, Tam TW. Factors influencing childhood influenza immunization. CMAJ 2003; 168:39-41.
38. Bonanni P, Bergamini M. Factors influencing vaccine uptake in Italy. Vaccine 2001; 20:58-12.
39. Da Villa G. Rationale for the infant and adolescent vaccination programmes in Italy. Vaccine 2000; 18:531-4
40. BOHEME study. http://www.recercaesantita.it/medicinaesanita/bohegenn.PPT (accessed in February 2006).
41. Van Cauwenberge P, Berdeaux G, Morineau A, Smadjia C, Allaire JM. For the Rhinitis Survey Study Group: Use of diagnostics clusters to assess the economic consequences of rhinopharyngitis in children in Italy and France during winter. Clin Ther 1999; 21:404-21.
42. Di Ciommo V, Russo P, Attanasio E, Di Liso G, Graziani C, Caprino L. Clinical and economic outcomes of pneumonia in children: A longitudinal observational study in an Italian paediatric hospital. J Evaluation in Clinical Practice 2002; 8:341-8.
43. Resi D, Milandri M, Moro ML. Emilia Romagna Study Group on the use of antibiotics in children: Antibiotic prescriptions in children. J Antimicrob Chemother 2003; 52:282-286.
44. Programma Nazionale Linee-Guida. http://www.pnlg.it (accessed in February 2006).
45. Sessa A, Bettoncelli G, D'Ambrosio G, Lucioni G, Costa B, Bamfi F. Lo studio 606: L'influenza ai raggi X. http://www.simg.it/servizi/ servizi_riviste2000/numero2/606.htm (accessed in February 2006).
46. Thiry N, Beutels P, Tancredi F, Romano L, Zanetti A, Bonanni R Gabutti G, Van Damme P. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22:3546-2.
47. Italian inflation rates. http://www.istat.il/prezzi/precon/rivalutazioni (accessed in February 2006).
48. Sessa A, Costa B, Bamfi F, Bettoncelii G, D'Ambrosio G. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001; 18:629-34.
49. Colombo GI, Nicosia V, Lesma A, Madera A, Caruggi M, Serra G. Analisi costi-benefici di una strategia vaccinale antiinfluenzale condotta presso una società del gruppo ENI (Snamprogetti). Pharmacoeconomics-Italian Research Articles 2001; 3:71-80.
50. Colombo GL. Cost-of-illness delle malattie pneumococciche nel bambino in Italia. Ann Ig 2002; 14:373-88.
51. Banca d'Italia. Italian household budgets in year 2002. www.bancaditalia.it/pubblicazioni (accessed in February 2006).
52. Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia. www.aihw.gov.au/publications/health/bdia http:(accessed February 2006).
53. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-8.
54. Beutels P, Bonnani P, Tormans G, Canale F, Crovari P. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 1999; 17:2400-9.
55. Da Villa G, Sepe A. Immunization programmes against hepatitis B virus infection in Italy: Cost-effectiveness. Vaccine 1999; 17:1734-8.
56. De Campora E, Pizzuti R. Use of the economic evaluation in the comparison of different vaccination programs against Haemophilus influenzae type b disease. Ann Ig 1995; 7:329-338.
57. Marchetti M, Colombo GL. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 2005; 23:4565-4576.
58. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della merodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoeconomics Italian Research Articles 2003; 5:53-67.
59. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2005, [Epub ahead of print].
60. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106:973-6.
61. Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108:E24.
62. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine 2005; 23:1004-14.
63. Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuramidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ 2005; 6:244-52.
64. Carrat F, Shaler C, Rogez S, Leruez-Ville M, Freymuth F, Le Gales C. Influenza burden of illness: Estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002; 162:1842-8.